Is a urine culture result of greater than 100,000 CFU/mL Aerococcus urinae indicative of a true urinary tract infection that requires antimicrobial therapy, and what is the recommended treatment regimen?

Aerococcus urinae >100,000 CFU/mL: Treatment Recommendation

A urine culture growing >100,000 CFU/mL of Aerococcus urinae in a symptomatic patient represents a true urinary tract infection requiring antimicrobial therapy, with treatment selection based on susceptibility testing and clinical severity.

Clinical Context and Significance

Aerococcus urinae is an emerging uropathogen that is not addressed in standard UTI guidelines 1, 2, 3, 4. The provided EAU 2024 guidelines focus on common uropathogens (E. coli, Proteus, Klebsiella, Pseudomonas, Serratia, Enterococcus) but do not specifically mention Aerococcus species 1.

However, the fundamental principles of UTI management still apply:

Decision Algorithm

Step 1: Confirm True Infection vs. Asymptomatic Bacteriuria

• If patient has UTI symptoms (dysuria, frequency, urgency, suprapubic pain, fever, flank pain, costovertebral angle tenderness): This is a true infection requiring treatment
• If patient is completely asymptomatic: This represents asymptomatic bacteriuria (ASB)
  • Do NOT treat in most populations 1, 2, 4
  • Exception: Screen for and treat ASB only before urological procedures breaching the mucosa or in pregnant women 1, 4

Step 2: Classify the UTI Type

Determine if uncomplicated vs. complicated:

• Complicated UTI if patient has 1:
  • Male sex
  • Urinary obstruction
  • Foreign body/catheter
  • Incomplete voiding
  • Diabetes mellitus
  • Immunosuppression
  • Recent instrumentation
  • Healthcare-associated infection

Step 3: Treatment Selection

Critical caveat: Aerococcus urinae has unique susceptibility patterns not covered by standard empiric regimens. Obtain susceptibility testing and tailor therapy accordingly.

For Uncomplicated Cystitis (symptomatic women without complicating factors):

While awaiting susceptibilities, empiric options per EAU guidelines 1:

• Oral fluoroquinolones (ciprofloxacin 500-750 mg BID for 7 days OR levofloxacin 750 mg daily for 5 days) if local resistance <10%
• Oral cephalosporins (cefpodoxime 200 mg BID for 10 days)

For Uncomplicated Pyelonephritis:

• Outpatient: Ciprofloxacin 500-750 mg BID for 7 days OR levofloxacin 750 mg daily for 5 days 1
• Hospitalized: IV fluoroquinolone, aminoglycoside (with or without ampicillin), or extended-spectrum cephalosporin/penicillin 1

For Complicated UTI:

Strong recommendation 1:

• Amoxicillin plus aminoglycoside, OR
• Second-generation cephalosporin plus aminoglycoside, OR
• IV third-generation cephalosporin
• Duration: 7-14 days (14 days for men when prostatitis cannot be excluded) 1

Critical Pitfalls to Avoid

1. Do not treat asymptomatic bacteriuria unless patient is pregnant or undergoing urological mucosal procedures 1, 2, 4

2. Do not assume standard E. coli susceptibility patterns - Aerococcus urinae may have different resistance profiles requiring susceptibility-guided therapy

3. Do not use nitrofurantoin, fosfomycin, or pivmecillinam for pyelonephritis - insufficient efficacy data 1

4. Avoid fluoroquinolones empirically if local resistance >10%, patient is from urology department, or has used fluoroquinolones in last 6 months 1

5. Address underlying complicating factors - antimicrobial therapy alone is insufficient for complicated UTI without managing obstruction, foreign bodies, or other anatomic abnormalities 1

Treatment Duration Adjustment

• Haemodynamically stable and afebrile ≥48 hours: Consider shorter 7-day course for complicated UTI 1
• Men: Default to 14 days when prostatitis cannot be excluded 1
• Duration should be closely related to treatment of underlying abnormality 1